Exelixis (EXEL) Change in Receivables (2010 - 2026)
Exelixis (EXEL) recorded quarterly Change in Receivables of $42.0 million in Q2 2026, up 284.27% quarter-over-quarter from -$22.8 million in Q1 2026, and up 160.75% on a YoY basis from $16.1 million in Q2 2025.
Exelixis (EXEL) Change in Receivables (2010 - 2026) Analysis & Trends
Exelixis' Change in Receivables history runs 17 years deep, the most recent figure standing at $42.0 million for Q2 2026.
- In Q2 2026, Change in Receivables rose 160.75% year-over-year to $42.0 million; the TTM figure through Apr 2026 stood at $47.3 million (up 15.68% YoY), while the FY2026 annual figure was $21.4 million, down 23.44% from the prior year.
- Change in Receivables was $42.0 million for Q2 2026 at Exelixis, up from -$22.8 million in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $156.0 million in Q2 2024 to a low of -$127.0 million in Q3 2024.
- Historically, Change in Receivables has averaged $2.8 million across 5 years, with a median of $3.2 million in 2024.
- The sharpest annual moves came in 2023 and 2024: Change in Receivables tumbled 27370.73% in 2023, then jumped 18223.93% in 2024.
- A 5-year view of Change in Receivables shows it stood at $41000.0 in 2022, then sank by 27370.73% to -$11.2 million in 2023, then tumbled by 1036.08% to -$127.0 million in 2024, then soared by 113.67% to $17.4 million in 2025, then jumped by 141.97% to $42.0 million in 2026.
- The last three Change in Receivables figures came in at $42.0 million (Q2 2026), -$22.8 million (Q1 2026), and $17.4 million (Q4 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | 22,529.00 |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | -39.80 Mn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | -4.08 Mn |
| 10 | Exelixis | 13.71 Bn | 12.93 Bn | 590.86 Mn | 42.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | 42.03 Mn |
| Apr 3, 2026 | 42.03 Mn |
| Jan 2, 2026 | -22.81 Mn |
| Jan 2, 2026 | -22.81 Mn |
| Oct 3, 2025 | 17.37 Mn |
| Oct 3, 2025 | 17.37 Mn |
| Jul 4, 2025 | 10.72 Mn |
| Jul 4, 2025 | 10.72 Mn |
| Apr 4, 2025 | 16.12 Mn |
| Apr 4, 2025 | 16.12 Mn |
| Jan 3, 2025 | -4.24 Mn |
| Jan 3, 2025 | -4.24 Mn |
| Sep 27, 2024 | -127.03 Mn |
| Sep 27, 2024 | -127.03 Mn |
| Jun 28, 2024 | 156.05 Mn |
| Jun 28, 2024 | 156.05 Mn |
| Mar 29, 2024 | 3.17 Mn |
| Mar 29, 2024 | 3.17 Mn |
| Dec 29, 2023 | -11.18 Mn |
| Dec 29, 2023 | -11.18 Mn |